Verastem, Inc. (NASDAQ:VSTM)‘s stock had its “buy” rating reiterated by stock analysts at Oppenheimer Holdings, Inc. in a report issued on Thursday. They currently have a $6.00 price objective on the biopharmaceutical company’s stock. Oppenheimer Holdings, Inc.’s target price points to a potential upside of 29.87% from the stock’s current price.

A number of other equities research analysts also recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $10.00 price target (up from $6.50) on shares of Verastem in a report on Thursday, September 7th. Cantor Fitzgerald upgraded Verastem from a “neutral” rating to an “overweight” rating and set a $2.00 price objective on the stock in a report on Wednesday, September 6th. ValuEngine downgraded Verastem from a “hold” rating to a “sell” rating in a report on Friday, September 1st. Cann restated a “buy” rating on shares of Verastem in a report on Wednesday, August 16th. Finally, Zacks Investment Research downgraded Verastem from a “hold” rating to a “sell” rating in a report on Saturday, August 12th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. Verastem presently has an average rating of “Hold” and a consensus target price of $5.04.

Verastem (VSTM) traded down 2.338% during trading on Thursday, reaching $4.512. 448,782 shares of the company’s stock traded hands. Verastem has a 12 month low of $1.05 and a 12 month high of $5.71. The stock’s market capitalization is $166.91 million. The company has a 50-day moving average of $4.59 and a 200 day moving average of $3.09.

Verastem (NASDAQ:VSTM) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.02). On average, equities research analysts expect that Verastem will post ($1.38) earnings per share for the current fiscal year.

WARNING: This article was first posted by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/10/12/verastem-inc-vstm-rating-reiterated-by-oppenheimer-holdings-inc.html.

Institutional investors and hedge funds have recently modified their holdings of the company. Artal Group S.A. acquired a new position in shares of Verastem in the 2nd quarter valued at about $1,090,000. Renaissance Technologies LLC grew its stake in shares of Verastem by 20.0% in the 1st quarter. Renaissance Technologies LLC now owns 1,226,600 shares of the biopharmaceutical company’s stock valued at $2,539,000 after buying an additional 204,400 shares in the last quarter. Alpine Woods Capital Investors LLC bought a new stake in shares of Verastem in the 2nd quarter valued at approximately $109,000. Howland Capital Management LLC grew its stake in shares of Verastem by 16.5% in the 2nd quarter. Howland Capital Management LLC now owns 294,007 shares of the biopharmaceutical company’s stock valued at $641,000 after buying an additional 41,616 shares in the last quarter. Finally, OxFORD Asset Management LLP bought a new stake in shares of Verastem in the 2nd quarter valued at approximately $234,000. Institutional investors own 24.19% of the company’s stock.

Verastem Company Profile

Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.

Analyst Recommendations for Verastem (NASDAQ:VSTM)

Receive News & Ratings for Verastem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.